- Home
- KROS vs MAX Comparison
KROS vs MAX Comparison
Compare KROS & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- MAX
- Stock Information
- Founded
- KROS 2015
- MAX 2014
- Country
- KROS United States
- MAX United States
- Employees
- KROS 160
- MAX N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- MAX Industrial Machinery/Components
- Sector
- KROS Health Care
- MAX Industrials
- Exchange
- KROS Nasdaq
- MAX Nasdaq
- Market Cap
- KROS 589.8M
- MAX 613.7M
- IPO Year
- KROS 2020
- MAX 2020
- Fundamental
- Price
- KROS $14.56
- MAX $10.50
- Analyst Decision
- KROS Buy
- MAX Buy
- Analyst Count
- KROS 11
- MAX 8
- Target Price
- KROS $68.83
- MAX $22.38
- AVG Volume (30 Days)
- KROS 2.0M
- MAX 506.2K
- Earning Date
- KROS 02-26-2025
- MAX 02-18-2025
- Dividend Yield
- KROS N/A
- MAX N/A
- EPS Growth
- KROS N/A
- MAX N/A
- EPS
- KROS N/A
- MAX 0.19
- Revenue
- KROS $651,000.00
- MAX $681,230,000.00
- Revenue This Year
- KROS $224.66
- MAX $124.41
- Revenue Next Year
- KROS N/A
- MAX $31.11
- P/E Ratio
- KROS N/A
- MAX $55.94
- Revenue Growth
- KROS 8037.50
- MAX 72.47
- 52 Week Low
- KROS $13.96
- MAX $10.21
- 52 Week High
- KROS $73.00
- MAX $25.78
- Technical
- Relative Strength Index (RSI)
- KROS 22.18
- MAX 42.21
- Support Level
- KROS $15.59
- MAX $11.35
- Resistance Level
- KROS $16.49
- MAX $11.83
- Average True Range (ATR)
- KROS 0.80
- MAX 0.45
- MACD
- KROS 0.95
- MAX 0.13
- Stochastic Oscillator
- KROS 16.31
- MAX 40.84
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.